Fosamax and Osteonecrosis of the Jaw: Legal Considerations and Statute of Limitations in Texas

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy of General Health Information on Medication Risks

For decades, general health and science information has served as the foundation for public understanding of medication risks and benefits. In this legacy context, audiences have been educated about the importance of adhering to prescribed treatments while remaining aware of potential side effects. This broad framework has empowered individuals to make informed decisions about their healthcare, particularly regarding chronic conditions that require long-term pharmacological management. Within this heritage, a specific area of concern has emerged: the relationship between bisphosphonate medications like Fosamax and the rare but serious condition of osteonecrosis of the jaw. While general health education traditionally focuses on patient-level awareness, a pivot is necessary to address the occupational dimension of this risk. In mass production environments—such as pharmaceutical manufacturing, dental laboratories, or industrial settings where workers may handle or be exposed to bisphosphonate compounds—the exposure profile differs fundamentally from that of a patient taking a prescribed dose. Workers may encounter these substances through inhalation, dermal contact, or incidental ingestion over extended shifts, raising distinct questions about cumulative exposure and potential health consequences. This transition from a patient-centered health information model to an occupational exposure framework requires careful consideration of how legacy knowledge about medication risks can be adapted to protect workers. The focus shifts from voluntary medication use to involuntary workplace exposure, where regulatory and safety protocols must account for unique exposure pathways and durations.

Bridging to Occupational and Legal Contexts

While the legacy of general health information has provided a foundation for understanding medication risks, the specific case of Fosamax and osteonecrosis of the jaw (ONJ) demands a more focused examination, particularly for individuals who may have been exposed in occupational settings or who are considering legal action. The transition from patient-centered education to occupational and legal frameworks is essential because the exposure pathways and risk profiles differ. For patients prescribed Fosamax, the risk of ONJ is a known but rare adverse effect. However, for workers in environments where bisphosphonates are manufactured or handled, the exposure may be chronic and involuntary, raising distinct concerns about cumulative harm. Additionally, for those who have developed ONJ after Fosamax use, understanding the statute of limitations for filing a claim is critical. In Texas, personal injury claims generally must be filed within two years from the date the injury was discovered or reasonably should have been discovered. Given the variable time to onset of ONJ symptoms—ranging from one day to several months after starting Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)—the timeline between exposure and documented harm can be complex. Patients who developed ONJ after prolonged use may have a delayed discovery of the injury, which could affect the start of the limitations period. Legal consultation is recommended to assess individual circumstances.

Fosamax and Osteonecrosis of the Jaw: Medical Evidence

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, consideration of drug discontinuation after 3 to 5 years of use is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The mechanistic pathways linking Fosamax to ONJ involve the drug's effect on bone remodeling. Bisphosphonates like alendronate inhibit osteoclast-mediated bone resorption, which can lead to suppressed bone turnover. In the jawbone, this suppression may impair the normal healing response to microtrauma or dental procedures, contributing to the development of ONJ. A multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research underscores the unique vulnerability of the jawbone to bisphosphonate therapy. The time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Discontinuation of the drug is recommended if severe symptoms develop, and most patients experience relief of symptoms after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a subset of patients may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Statute of Limitations for Fosamax Claims in Texas

For affected patients in Texas considering settlement-related considerations, the statute of limitations is a critical factor. In Texas, personal injury claims generally must be filed within two years from the date the injury was discovered or reasonably should have been discovered. Given the variable time to onset of ONJ symptoms—ranging from one day to several months after starting Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)—the timeline between exposure and documented harm can be complex. Patients who developed ONJ after prolonged use may have a delayed discovery of the injury, which could affect the start of the limitations period. Legal consultation is recommended to assess individual circumstances. Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw, detailing the association with bisphosphonate use and known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The warnings also note that in placebo-controlled clinical studies of Fosamax, the percentages of patients with gastrointestinal symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the label does not provide specific guidance on the statute of limitations for legal claims in Texas or other jurisdictions.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Fosamax-related osteonecrosis of the jaw claims in Texas?

In Texas, personal injury claims generally must be filed within two years from the date the injury was discovered or reasonably should have been discovered. For Fosamax-induced ONJ, the onset of symptoms can vary from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), so the discovery date may be delayed. It is important to consult with an attorney to determine the applicable deadline based on individual circumstances.

What are the known risk factors for developing osteonecrosis of the jaw from Fosamax?

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with longer duration of bisphosphonate use.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.